{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:23:47Z","timestamp":1790634227220,"version":"4.1.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"11","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Rurioctocog alfa pegol is an extended\u2013half-life full-length recombinant factor VIII (FVIII) bound to 20-kDa polyethylene glycol (PEG) that has been shown to be well tolerated and efficacious in the treatment and prevention of bleeding events in previously treated patients with severe hemophilia A. Here, we present a comprehensive analysis of immunogenicity data collected during 6 clinical studies of rurioctocog alfa pegol, including a total of 360 unique previously treated patients with severe hemophilia A. The analysis included treatment-emerging FVIII-neutralizing antibodies (FVIII inhibitors); preexisting and treatment-emerging antibodies binding to FVIII, PEG-FVIII, or PEG; and treatment-emerging antibodies binding to Chinese hamster ovary host cell proteins. Moreover, the potential association between the presence of these binding antibodies and adverse events (AEs) observed in patients was investigated, and the potential impact of these antibodies on the incremental recovery of rurioctocog alfa pegol in patients was analyzed. Overall, the data indicate that rurioctocog alfa pegol is not associated with any unexpected immunogenicity characteristics. Of 360 patients, 1 patient developed a transient FVIII inhibitor with a titer of 0.6 Bethesda units per mL, which was not associated with any serious AEs. Antibodies binding to FVIII, PEG-FVIII, or PEG were not detected at the time when the inhibitor was present. Moreover, 54 of 360 patients either entered the clinical studies with preexisting binding antibodies or developed these antibodies after exposure to rurioctocog alfa pegol. These antibodies were transient in most patients and did not show any causal relationship to either AEs or spontaneous bleeding episodes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011780","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T20:34:38Z","timestamp":1712090078000},"page":"2726-2739","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A"],"prefix":"10.1182","volume":"8","author":[{"given":"Frank M.","family":"Horling","sequence":"first","affiliation":[{"name":"1Institute Krems Bioanalytics, IMC University of Applied Sciences Krems, Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-4610","authenticated-orcid":false,"given":"Birgit M.","family":"Reipert","sequence":"additional","affiliation":[{"name":"1Institute Krems Bioanalytics, IMC University of Applied Sciences Krems, Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Allacher","sequence":"additional","affiliation":[{"name":"1Institute Krems Bioanalytics, IMC University of Applied Sciences Krems, Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1705-7850","authenticated-orcid":false,"given":"Werner","family":"Engl","sequence":"additional","affiliation":[{"name":"2Baxalta Innovations GmbH, a Takeda company, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Pan","sequence":"additional","affiliation":[{"name":"3Takeda Development Center Americas, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9721-4993","authenticated-orcid":false,"given":"Srilatha","family":"Tangada","sequence":"additional","affiliation":[{"name":"3Takeda Development Center Americas, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"issue":"8","key":"2024061013552968700_bib1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14712598.2021.1940133","article-title":"Bispecific antibodies for the treatment of hemophilia A","volume":"22","author":"Shima","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"2024061013552968700_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024061013552968700_bib3","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH11-09-0642","article-title":"Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A","volume":"107","author":"Auerswald","year":"2012","journal-title":"Thromb Haemost"},{"issue":"21","key":"2024061013552968700_bib4","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A\u00a0randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024061013552968700_bib5","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"Reipert","year":"2020","journal-title":"Blood Adv"},{"issue":"102","key":"2024061013552968700_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2516.2010.02235.x","article-title":"Inhibitors in previously treated patients: a review of the literature","volume":"16","author":"Kempton","year":"2010","journal-title":"Haemophilia"},{"issue":"1","key":"2024061013552968700_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-2516.1998.0146c.x","article-title":"Inhibitors occur more frequently in African-American and Latino haemophiliacs","volume":"4","author":"Aledort","year":"1998","journal-title":"Haemophilia"},{"issue":"3","key":"2024061013552968700_bib8","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1111\/j.1365-2516.2011.02739.x","article-title":"Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database","volume":"18","author":"Carpenter","year":"2012","journal-title":"Haemophilia"},{"issue":"12","key":"2024061013552968700_bib9","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"issue":"1 suppl 1","key":"2024061013552968700_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.seminhematol.2003.11.016","article-title":"Environmental and genetic factors influencing inhibitor development","volume":"41","author":"Oldenburg","year":"2004","journal-title":"Semin Hematol"},{"issue":"12","key":"2024061013552968700_bib11","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2024061013552968700_bib12","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood-2008-08-174987","article-title":"Quantitation of anti-factor VIII antibodies in human plasma","volume":"113","author":"Krudysz-Amblo","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2024061013552968700_bib13","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1160\/TH10-10-0668","article-title":"Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors","volume":"105","author":"Lebreton","year":"2011","journal-title":"Thromb Haemost"},{"issue":"6","key":"2024061013552968700_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2024061013552968700_bib15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2024061013552968700_bib16","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A","volume":"129","author":"Cannav\u00f2","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2024061013552968700_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaut.2007.07.007","article-title":"Homeostatic roles of naturally occurring antibodies: an overview","volume":"29","author":"Lutz","year":"2007","journal-title":"J\u00a0Autoimmun"},{"issue":"15","key":"2024061013552968700_bib18","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.4103\/0366-6999.233604","article-title":"Pharmacokinetic studies of factor VIII in Chinese boys with severe hemophilia A: a single-center study","volume":"131","author":"Chen","year":"2018","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"2024061013552968700_bib19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2141.1995.tb05325.x","article-title":"Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels","volume":"91","author":"Fijnvandraat","year":"1995","journal-title":"Br J Haematol"},{"issue":"8","key":"2024061013552968700_bib20","doi-asserted-by":"crossref","first-page":"e6745","DOI":"10.1371\/journal.pone.0006745","article-title":"Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients","volume":"4","author":"Fischer","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"2024061013552968700_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/hae.12592","article-title":"Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A","volume":"21","author":"Kepa","year":"2015","journal-title":"Haemophilia"},{"issue":"11","key":"2024061013552968700_bib22","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood.2019000190","article-title":"Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients","volume":"134","author":"Swystun","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024061013552968700_bib23","first-page":"494","article-title":"Factor VIII half-life and clinical phenotype of severe hemophilia A","volume":"90","author":"van Dijk","year":"2005","journal-title":"Haematologica"},{"issue":"1","key":"2024061013552968700_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-0037-1613759","article-title":"The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A","volume":"83","author":"Vlot","year":"2000","journal-title":"Thromb Haemost"},{"issue":"9","key":"2024061013552968700_bib25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2024061013552968700_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.13597","article-title":"Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII","volume":"15","author":"Reding","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2024061013552968700_bib27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"2024061013552968700_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"2024061013552968700_bib29","first-page":"S29","article-title":"BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation","volume":"32","author":"Turecek","year":"2012","journal-title":"H\u00e4mostaseologie"},{"key":"2024061013552968700_bib30","unstructured":"ADYNOVATE, antihemophilic factor (recombinant), PEGylated. Highlights of prescribing information. 2023. Baxalta US Inc, a Takeda company. Accessed 18 April 2024. https:\/\/www.shirecontent.com\/PI\/PDFs\/ADYNOVATE_USA_ENG.pdf."},{"key":"2024061013552968700_bib31","unstructured":"European Medicines Agency\n          . Summary of Product Characteristics-ADYNOVI, Rurioctocog Alfa Pegol. Accessed 18 April 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adynovi-epar-product-information_en.pdf."},{"issue":"6","key":"2024061013552968700_bib32","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jtha.2023.03.011","article-title":"Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII","volume":"21","author":"Pezeshkpoor","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024061013552968700_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/B978-0-444-64081-9.00004-8","volume-title":"Polymer-Protein Conjugates","author":"Turecek","year":"2020"},{"issue":"2","key":"2024061013552968700_bib34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A","volume":"23","author":"Mullins","year":"2017","journal-title":"Haemophilia"},{"issue":"5","key":"2024061013552968700_bib35","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/hae.13807","article-title":"Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: final results of a multicentre, single-arm phase III trial","volume":"25","author":"Gruppo","year":"2019","journal-title":"Haemophilia"},{"issue":"4","key":"2024061013552968700_bib36","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1111\/hae.14052","article-title":"Long-term safety and efficacy results from the phase 3b, open-label, multicentre continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A","volume":"26","author":"Chowdary","year":"2020","journal-title":"Haemophilia"},{"issue":"13","key":"2024061013552968700_bib37","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"key":"2024061013552968700_bib38","unstructured":"European Medicines Agency\n          . Committee for Medicinal Products for Human Use-Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. Accessed 19 July 2023.. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-first-version_en.pdf."},{"key":"2024061013552968700_bib39","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER)\n          . Draft Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. Accessed 19 July 2023.. http:\/\/www.nihs.go.jp\/dbcb\/immunogenicity\/FDA_2009_Assay%20Development%20for%20Immunogenicity%20Testing%20of%20Therapeutic%20Proteins_Draft.pdf."},{"issue":"suppl 1","key":"2024061013552968700_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ijlh.12352","article-title":"Pearls and pitfalls in factor inhibitor assays","volume":"37","author":"Adcock","year":"2015","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"2024061013552968700_bib41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/hae.13424","article-title":"Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review","volume":"24","author":"Miller","year":"2018","journal-title":"Haemophilia"},{"issue":"4","key":"2024061013552968700_bib42","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/bloodadvances.2022007529","article-title":"The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A","volume":"7","author":"Male","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2024061013552968700_bib43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/bloodadvances.2022008989","article-title":"Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination","volume":"7","author":"Valsecchi","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2024061013552968700_bib44","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1016\/j.jtha.2023.07.019","article-title":"Report on four cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII","volume":"21","author":"Hillarp","year":"2023","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2726\/2228502\/blooda_adv-2023-011780-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2726\/2228502\/blooda_adv-2023-011780-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T13:56:12Z","timestamp":1718027772000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/11\/2726\/515574\/Immunogenicity-profile-of-rurioctocog-alfa-pegol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011780","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}